Prevention of hepatic encephalopathy;Profilaxis de la encefalopatía hepática

Medicina Clinica

Volumn 142, Issue 11, 2014, Pages 512-514

  Morillas, Rosa M ^a,b   Sala, Marga ^a,b   Planas, Ramon ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Decompensated cirrhosis; Hepatic encephalopathy; Prevention

Indexed keywords

CENTRAL DEPRESSANT AGENT; DIURETIC AGENT; LACTITOL; LACTULOSE; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN; SUGAR ALCOHOL;

BACTERIAL PERITONITIS; DRUG USE; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER GRAFT; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; COMPLICATION; CONTRAINDICATIONS; HYPERAMMONEMIA; INTESTINE ABSORPTION; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); PERITONITIS; PORTOSYSTEMIC ANASTOMOSIS; POSTOPERATIVE COMPLICATIONS; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DIURETICS; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; INTESTINAL ABSORPTION; LACTULOSE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META-ANALYSIS AS TOPIC; PERITONITIS; PORTASYSTEMIC SHUNT, SURGICAL; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIFAMYCINS; RISK FACTORS; SUGAR ALCOHOLS;

EID: 84900465793     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2013.11.027     Document Type: Review

References (12)

1. J.S. Bajaj Review article: The modern management of hepatic encephalopathy Aliment Pharmacol Ther 31 2010 537 547
2. 4-induced cirrhosis plus total portal vein ligation: A new model for the study of hyperammonaemia and brain oedema Liver Int 30 2010 979 987
3. S.M. Riordan, and R. Williams Treatment of hepatic encephalopathy N Engl J Med 337 1997 473 479
4. B. Als-Nielsen, L.L. Gluud, and C. Gluud Non-absorbable disacharides for hepatic encephalopathy: Systematic review of randomised trials BMJ 328 2004 1046 1051
5. B.C. Sharma, P. Sharma, A. Agrawal, and S.K. Sarin Secondary prophylaxis of hepatic encephalopathy: An open-label randomized controlled trial of lactulose versus placebo Gastroenterology 137 2009 885 891
6. G. Odena, M. Miquel, A. Serafín, A. Galan, R. Morillas, and R. Planas et al. Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats World J Gastroenterol 18 2012 2084 2091
7. D.O. Maclayton, and A.E. Eaton-Maxwell Rifaximin for treatment of hepatic encephalopathy Ann Pharmacother 43 2009 77 84
8. K.R. Lawrence, and J.A. Klee Rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy Pharmacotherapy 28 2008 1019 1032
9. Q. Jiang, X.H. Jiang, M.H. Zheng, L.M. Jiang, Y.P. Chen, and L. Wang Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: A meta-analysis Eur J Gastroenterol Hepatol 20 2008 1064 1070
10. N.M. Bass, K.D. Mullen, A. Sanyal, F. Poordad, G. Neff, and C.B. Leevy et al. Rifaximin treatment in hepatic encephalopathy N Engl J Med 362 2010 1071 1081
11. A. Sanyal, N. Bass, F. Poordad, M.Y. Sheikh, K. Mullen, and S. Sigal et al. Rifaximin decreases venous ammonia concentrations and time-weighted average ammonia concentrations correlate with overt hepatic encephalopathy (HE) as assess by Conn score in a 6-month study J Hepatol 52 2010 S84 A195
12. A. Sanyal, N. Bass, K. Mullen, F. Poordad, A. Shaw, and K. Merchant et al. Rifaximin treatment improved quality of life in patients with hepatic encephalopathy: Results of a large, randomized, placebo-controlled trial J Hepatol 52 2010 S7 A15